Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

摘要

BackgroundChemotherapy decreases the risk of relapse and mortality in early-stage breast cancer (BC), but it comes with the risk of toxicity. Chemotherapy efficacy depends on relative dose intensity (RDI), and an RDI MethodsThis study enrolled women with stage I–III BC. Prior to adjuvant or neoadjuvant chemotherapy, peripheral blood was collected for biomarker measurement. Dose reductions and delays were captured and utilized to calculate the RDI delivered. Univariate and multivariate analyses were performed to describe the association between pre-chemotherapy IL-6, CRP, and D-dimer levels and an RDI ResultsA total of 159 patients (mean age 58?years, range 30–81, SD 11.3) with stage I–III BC were enrolled. An RDI p =?0.006) and D-dimer (OR 2.32, 95% CI 1.27–4.24; p =?0.006) levels, increased age ( p =?0.001), increased number of comorbidities ( p =?0.01), and decreased physical function by the Medical Outcomes Survey Activities of Daily Living (ADL) Scale ( p =?0.009) in univariate analysis. A multivariate model, including two biomarkers (IL-6 and D-dimer), age, ADL, BC stage, and chemotherapy regimen, demonstrated a significant association between the increased biomarkers and reduced RDI p =?0.04). ConclusionsIncreased pre-chemotherapy biomarkers of aging (IL-6 and D-dimer) are associated with reduced RDI ( Trial registrationClinicalTrials.gov, NCT01030250 . Registered on 3 November 2016.